
    
      This study was a double-blinded, multicenter, efficacy, and safety study of KX2-391 ointment
      administered topically to the face or scalp of participants with AK.

      The study consisted of Screening, Treatment, Follow-up, and Recurrence Follow-up Periods.
      Eligible participants received up to 5 consecutive days of topical treatment. Efficacy
      (lesion counts) and safety evaluations were performed.
    
  